Biomarker Testing
Pre-clinicalUNKNOWN 0 watching 0 views this week💤 Quiet
23
Development Stage
1
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Stage I-IV Breast Cancer (Neo-adjuvant, Adjuvant, Locally Advanced and Metastatic)
Conditions
Stage I-IV Breast Cancer (Neo-adjuvant, Adjuvant, Locally Advanced and Metastatic)
Trial Timeline
Nov 1, 2009 → Dec 1, 2019
NCT ID
NCT01022086About Biomarker Testing
Biomarker Testing is a pre-clinical stage product being developed by Roche for Stage I-IV Breast Cancer (Neo-adjuvant, Adjuvant, Locally Advanced and Metastatic). The current trial status is unknown. This product is registered under clinical trial identifier NCT01022086. Target conditions include Stage I-IV Breast Cancer (Neo-adjuvant, Adjuvant, Locally Advanced and Metastatic).
Hype Score Breakdown
Clinical
5
Activity
2
Company
10
Novelty
2
Community
1
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT01022086 | Pre-clinical | UNKNOWN |
Competing Products
20 competing products in Stage I-IV Breast Cancer (Neo-adjuvant, Adjuvant, Locally Advanced and Metastatic)